If you have polycystic ovary syndrome (PCOS) and are trying to conceive, the good news is that fertility treatment here is not guesswork. There is a clear, evidence-based order, and knowing it helps you understand what your clinician is recommending and why.
PCOS, renamed polyendocrine metabolic ovarian syndrome (PMOS) in 2026 to reflect its whole-body hormonal and metabolic nature, is the most common cause of anovulation and works against fertility mainly by disrupting ovulation. [4] Most fertility treatment is therefore about restoring ovulation, in a stepwise way, starting with the least invasive options.
The treatment ladder
The 2023 international guideline lays out a sequence, and the trials behind it are unusually clear. [1]
| Step | Treatment | What the evidence shows |
|---|---|---|
| 1 | Weight and lifestyle | First-line; can restore ovulation and improves the effect of later steps [1] |
| 2 | Letrozole | First-line medicine for ovulation induction, recommended over clomiphene [1]; more live births than clomiphene (27.5% vs 19.1%) [2] |
| 3 | Clomiphene or metformin | Clomiphene is an alternative; metformin can be added, especially with insulin resistance or higher weight [1] |
| 4 | Specialist options | Gonadotropins or in vitro fertilization if first-line steps do not succeed [1] |
The order is deliberate. Each rung is more involved than the last, so treatment starts where the balance of benefit and burden is best and escalates only if needed.
Why letrozole leads
Letrozole is the standout. The guideline recommends it as the first-line medicine for ovulation induction in women with the syndrome and no other infertility factors, and specifically advises using it rather than clomiphene to improve ovulation, clinical pregnancy, and live-birth rates. [1]
The evidence is strong. In the largest head-to-head trial, letrozole led to a live birth in 27.5 percent of women with the condition, compared with 19.1 percent on clomiphene, with higher ovulation rates too. [2] A meta-analysis of 42 trials and 7,935 women reached the same conclusion: letrozole improves live-birth and pregnancy rates compared with clomiphene. [3] For the wider menu of options, see polycystic ovary syndrome treatments ranked by the evidence.
Where metformin and weight fit
Metformin is not the star of ovulation induction, but it earns a supporting role. The guideline notes metformin can be used, particularly with higher weight or insulin resistance, while being clear that more effective ovulation agents exist. [1] Because insulin resistance is common in the condition and feeds the hormonal imbalance behind anovulation, treating the metabolic side can help fertility and long-term health together. For that angle, see metformin for polycystic ovary syndrome after menopause and inositol for polycystic ovary syndrome.
Weight and lifestyle changes sit at the base of the ladder for the same reason: even modest changes can restore ovulation and strengthen the effect of medicines. [1]
Where the evidence is limited
It is honest to say the evidence thins as you climb the ladder. The letrozole and clomiphene comparison is backed by large trials, but second-line steps like gonadotropins and in vitro fertilization are individualized and less about a single head-to-head number. [1] Success also depends on age, weight, insulin resistance, and whether other infertility factors are present, so published averages are a starting point, not a personal forecast. This is why the plan belongs with a clinician who can weigh your specifics.
Who this fits
This ladder fits women with the condition who are actively trying to conceive and want to understand the sequence and evidence behind their options. It is most useful for making sense of why a clinician starts with lifestyle and letrozole rather than jumping to in vitro fertilization.
It is a poor fit for self-directed treatment. Ovulation-inducing medicines require monitoring, and taking them without guidance risks multiple pregnancy and other complications. If you are over 35, or have been trying for six months to a year without success, that is a reason to seek assessment rather than keep waiting.
Red flags worth attention
- More than a year of trying to conceive, or six months if over 35, which warrants a fertility evaluation.
- Periods that stop for months or become very heavy, which needs evaluation to protect the uterine lining.
- Severe pelvic pain, or on fertility medicines, rapid bloating and shortness of breath, which are warning signs that need prompt care.
What to ask your clinician
- Am I ovulating, and if not, is letrozole the right first step for me?
- Would weight or insulin changes improve my odds before or alongside medicine?
- Should metformin be part of my plan given my metabolic picture?
- Given my age, how quickly should we move through the steps?
- What monitoring will I need on ovulation-inducing medicine?
- At what point should we involve a fertility specialist or consider in vitro fertilization?
Bottom line
Polycystic ovary syndrome fertility treatment follows a clear ladder: weight and lifestyle first, then letrozole as the first-line medicine to induce ovulation, recommended over clomiphene, with metformin as an adjunct and specialist options later. [1] The evidence for letrozole is strong, with more live births than clomiphene in the largest trial and across a 42-trial meta-analysis. [2] [3]
Which rung is right depends on your age, weight, and other fertility factors, so the ladder is a map, not a self-service menu. Walking it with a clinician, who can also watch the metabolic side of the syndrome, is what turns a treatable cause of infertility into a real plan.
References
[1] Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43-G64. https://pmc.ncbi.nlm.nih.gov/articles/PMC10505534/
[2] Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-29. doi:10.1056/nejmoa1313517 https://pubmed.ncbi.nlm.nih.gov/25006718/
[3] Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;5(5):CD010287. doi:10.1002/14651858.cd010287.pub3 https://pubmed.ncbi.nlm.nih.gov/29797697/
[4] World Health Organization. Polycystic ovary syndrome. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome